NCT03351231View on ClinicalTrials.gov

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 27, 2017

Primary Completion Date

August 28, 2018

Study Completion Date

August 28, 2018

Conditions
Cancer
Interventions
DRUG

BMS-986242

Specified dose on specified days

BIOLOGICAL

Nivolumab

Specified dose on specified days

Trial Locations (4)

21287

Local Institution, Baltimore

90033

Hoag Memorial Hospital Presbyterian, Los Angeles

USC Norris Comprehensive Cancer Center, Los Angeles

35294-3300

University Of Alabama At Birmingham, Birmingham

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY